enVVeno Medical Corporation (NVNO)

NASDAQ: NVNO · IEX Real-Time Price · USD
6.05
-0.15 (-2.42%)
At close: Feb 27, 2024, 4:00 PM
6.15
+0.10 (1.65%)
After-hours: Feb 27, 2024, 7:42 PM EST
-2.42%
Market Cap 82.56M
Revenue (ttm) n/a
Net Income (ttm) -24.05M
Shares Out 13.32M
EPS (ttm) -2.15
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 293,928
Open 6.27
Previous Close 6.20
Day's Range 5.70 - 6.40
52-Week Range 2.51 - 6.77
Beta 1.07
Analysts n/a
Price Target n/a
Earnings Date Mar 12, 2024

About NVNO

enVVeno Medical Corporation, a clinical med-tech company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of chronic venous disease. Its VenoValve is implanted in the femoral vein and acts as a one-way valve to help restore proper blood flow in the leg. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Med... [Read more]

Industry Medical Devices
Sector Healthcare
Founded 1987
Employees 30
Stock Exchange NASDAQ
Ticker Symbol NVNO
Full Company Profile

Financial Performance

Financial Statements

News

Hancock Jaffe to Participate in the Duologue Series Virtual Webinar Hosted by Ladenburg Thalmann

Live webinar followed by Q&A on Monday, September 27th at 1:00 PM ET with Robert Berman Chief Executive Officer of Hancock Jaffe Laboratories IRVINE, CA / ACCESSWIRE / September 24, 2021 / Hancock Jaf...

2 years ago - Accesswire

Hancock Jaffe To Rebrand As enVVeno Medical

Hancock Jaffe Laboratories Inc (NASDAQ: HJLI) will change its name to enVVeno Medical Corporation and start under a new ticker, "NVNO," from October 1. The Company will also narrow its strategic focus...

2 years ago - Benzinga

Hancock Jaffe Announces Corporate Rebranding to Reflect Prioritization of its Development Pipeline on Venous Disease Programs

- Hancock Jaffe changing name to enVVeno Medical Corporation and ticker symbol to NASDAQ: NVNO, effective October 1, 2021 - - Development strategy to focus on venous disease and advancement of the Ven...

2 years ago - Accesswire

Hancock Jaffe to Host Corporate Update Conference Call and Webcast on September 21, 2021

Conference call with live video webcast to be held on Tuesday, September 21st at 4:30 p.m. ET IRVINE, CA / ACCESSWIRE / September 15, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) ("Hancock Ja...

2 years ago - Accesswire

Hancock Jaffe Laboratories Announces $20 Million Registered Direct Offering Priced At-the-Market Under NASDAQ Rules

IRVINE, CA / ACCESSWIRE / September 7, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that it has enter...

2 years ago - Accesswire

Hancock Jaffe Highlights Two-Year Data For Venous Insufficiency Valve

Hancock Jaffe Laboratories Inc (NASDAQ: HJLI) announced two-year data post-VenoValve implantation in eight patients. Data will be presented at the Society for Vascular Surgery (SVS) Annual Meeting.

2 years ago - Benzinga

Hancock Jaffe Presents New Positive Two-Year VenoValve Data at the Society for Vascular Surgery Annual Meeting

Two-year VenoValve® data shows average improvements in reflux, disease manifestations and pain, of 63%, 60%, and 93%, respectively Patients with venous ulcers who experienced dramatic ulcer healing ha...

2 years ago - Accesswire

Hancock Jaffe Stock Surges On FDA Breakthrough Designation For Its Venous Insufficiency Device

The FDA has granted Breakthrough Device Designation status to  Hancock Jaffe Laboratories Inc's (NASDAQ:HJLI) VenoValve, the Company's lead product, currently set to begin its U.S. pivotal trial.  The...

2 years ago - Benzinga

FDA Grants Breakthrough Device Designation Status for Hancock Jaffe's VenoValve

- Goal of FDA Breakthrough Device Program is to speed up development by giving priority to devices that treat life-threatening or irreversibly debilitating conditions - Company preparing to begin SAVV...

2 years ago - Accesswire

Hancock Jaffe to Present at the Ladenburg Thalmann 2021 Healthcare Conference

Live webcast on Tuesday, July 13th at 1:00 PM ET IRVINE, CA / ACCESSWIRE / July 8, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) ("Hancock Jaffe" or the "Company"), a developer of medical devi...

2 years ago - Accesswire

Hancock Jaffe Principal Investigator Dr. Jorge Hernando Ulloa Presents VenoValve One Year First-In-Human Data at Charing Cross International Symposium

IRVINE, CA / ACCESSWIRE /  April 23, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that Dr. Jorge Hern...

3 years ago - Accesswire

First U.S. Patent Issues on Hancock Jaffe VenoValve

IRVINE, CA / ACCESSWIRE / April 7, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that the United State...

3 years ago - Accesswire

Hancock Jaffe Receives IDE Approval To Begin VenoValve U.S. Pivotal Trial

IRVINE, CA / ACCESSWIRE / April 5, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that the U.S. Food an...

3 years ago - Accesswire

Hancock Jaffe Submits IDE Application to FDA for VenoValve U.S. Pivotal Trial

IRVINE, CA / ACCESSWIRE / March 8, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that it has submitted...

3 years ago - Accesswire

Hancock Jaffe Concludes Successful VenoValve Pre-IDE Meeting with FDA

Company to Move Forward with Application for VenoValve U.S. Pivotal Trial IRVINE, CA / ACCESSWIRE / January 12, 2021 /  Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices t...

3 years ago - Accesswire

Hancock Jaffe Announces Executive Promotions

IRVINE, CA / ACCESSWIRE / December 30, 2020  / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that Dr. Hamed A...

3 years ago - Accesswire

Hancock Jaffe Deemed Compliant With All NASDAQ Continued Listing Requirements

Company Regains Compliance with NASDAQ Minimum Bid Requirement IRVINE, CA / ACCESSWIRE / December 21, 2020  / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restor...

3 years ago - Accesswire